Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...